The likely paths to a coronavirus vaccine
A difficult path
As the toll from COVID-19 keeps rising, both across the world and in India, the pressure to formulate a vaccine has never been greater. Here's a look at all the companies that are making headway.
Serum Institute of India
Working with British drug manufacturer AstraZeneca, the Indian institution is working on manufacturing a vaccine created by the Oxford University - currently the one showing best results - and scaling up production to a 100 million doses.
The Kiran Mazumdar-Shaw founded biopharmaceutical company is trialling its Itolizumab drug to see if it can combat the virus; a phase-II study is currently underway in three citites.
This Bangladesh based manufacturer is working on manufacturing Gilead's Remdesivir - the drug can mitigate the effects of COVID-19 - and has vouched to provide it freely at government hospitals.
Only the second place to start trials for Favipiravir, the Bengaluru based company is following in the footsteps of Glenmark and testing the flu medicine for its effectiveness against COVID-19.